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We identified a Rho guanine exchange factor (GEF) expressed as two splice variants, which differ only in either having
or lacking a Postsynaptic density 95, Disk large, Zona occludens-1 (PDZ) motif. The PDZ adaptor protein synectin bound
the longer splice variant, Syx1, which was targeted to the plasma membrane in a synectin-dependent manner. The shorter
variant, Syx2, was diffusely distributed in the cytoplasm. Fluorescence resonance energy transfer (FRET) imaging revealed
similar differences between the spatial patterns of active RhoA in Syx1 versus Syx2-expressing cells. Expression of Syx1
augmented endothelial cell (EC) migration and tube formation, whereas Syx2 expression did not. It appears, therefore,
that synectin-dependent targeting of Syx is critical to its contribution to these EC functions. Although agonist-stimulated
global RhoA activity was similar in Syx1- and Syx2-expressing cells, basal RhoA activity was surprisingly higher in the
latter. Out of 23 cell types, we found a significant level of endogenous Syx2 expression only in brain tumor cells, which
also exhibited high basal RhoA activity. We found that the activity level of JNK, which mediates transcriptional
regulation downstream of RhoA, is elevated in a Syx2-dependent manner in these cells, possibly contributing to their
tumorigenicity.
INTRODUCTION
Rho guanine exchange factors (GEFs) activate GTPases by
facilitating the replacement of GDP by GTP (Erickson and
Cerione, 2004). Because GEFs interact directly with their
effector GTPases (Snyder et al., 2002), Rho GEF targeting
determines the spatial pattern of GTPase activity. This tar-
geting does not appear to be regulated via a common mech-
anism shared by most Rho GEFs, however, as different
domains interacting with other proteins and phospholipids
determine the cellular positioning of various members of the
Rho GEF family (Rossman et al., 2005).
To date, postsynaptic density 95, disk large, zona occlu-
dens-1 (PDZ) binding motifs have been identified in four
Rho GEFs, two of which, the Rac1-specific Kalirin-7 (Penzes
et al., 2001) and the Rac1/Cdc42 GEF PIX (Park et al., 2003),
have been studied in neurons. Both Kalirin-7 and PIX
interact with multiple postsynaptic density PDZ scaffold
proteins. The third, neuroepithelioma transforming gene 1
(Net1), is a RhoA-specific GEF that has not yet been associ-
ated with any PDZ adaptor protein (Qin et al., 2005).
The fourth is a GEF with a PDZ-binding motif (GEF720)
that was recently identified in a human cDNA database
(Kikuno et al., 2002) and classified as RhoA-specific (De
Toledo et al., 2001). A rat orthologue of the same GEF (Tech,
a transcript highly enriched in cortex and hippocampus)
was independently identified and its catalytic properties
were characterized (Marx et al., 2005).
In parallel to the above studies, a DNA sequence corre-
sponding to the last 40 C-terminus residues of the mouse
orthologue of GEF720/Tech was cloned by yeast two-hybrid
screening of a 3T3 fibroblast cDNA library (M. Simons, per-
sonal communication) using synectin (Gao et al., 2000) as bait.
Synectin is an adaptor protein that contains a single PDZ
domain and is expressed early and ubiquitously (Zhang et al.,
2004). It is one of the most versatile PDZ proteins known to
date, with upwards of 20 binding partners, most of which are
transmembrane receptors (e.g., Gao et al., 2000; Blobe et al.,
2001; Lou et al., 2001) with type I C-terminus PDZ-binding
motifs conforming to the consensus sequence (S/T)-X-(V/A)
(Songyang et al., 1997).
We found that the recently identified synectin-binding Rho
GEF is expressed as two splice variants that differ only in either
having or lacking a PDZ motif, and took advantage of this
circumstance in order to dissect the function of the PDZ motif
in regulating Rho GEF activity and cell migration.
MATERIALS AND METHODS
Cloning of Mouse Syx1 and Syx2 cDNA
The sequence of human KIAA0720 (NCBI accession number AB018263) was
used for searching the NCBI mouse EST library. A putative full-length cDNA
sequence was assembled in silico based on overlapping EST entries that
spanned the entire coding sequence. Total RNA extracted (RNeasy, Qiagen,
Chatsworth, CA) from mouse heart ECs was used for amplifying by reverse
transcriptase PCR a 2.3-kb-long cDNA fragment corresponding to the central
region of the Syx cDNA with primers derived from the assembled sequence
(forward: GAAGAAAGCAAGGAGGAGACACA; reverse: CACAAAGTC-
TTGAAGGGAAG). The 5 and 3 ends of the fragment were extended (5/3
RACE, Roche, Indianapolis, IN) by RACE (5 primer: CTTCTTCTTCAT-
GGCTGGCAC; 3 primer: GTCACTCCCACCAGCGAG) using the same total
RNA pool. 5 RACE generated a 0.6-kb fragment and 3 RACE generated two 3
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fragments of 1.1 and 1.4 kb, corresponding to the Syx1 and Syx2 splice
variant, respectively. The start codon was identified by comparison between
human, mouse, and rat Syx genes and by GENESCAN (http://genes.mit.
edu/GENSCAN.html) exon analysis. Each fragment was inserted separately
into pCR2.1-TOPO (Invitrogen, Carlsbad, CA) by TA cloning and sequence-
verified. The 0.6-kb fragment was subcloned into the plasmid containing the
2.3-kb fragment using ScaI (5) and NotI (3). The 3 fragments of Syx1 and
Syx2 were both extended by PCR (forward primer: GCTCCCCCACCATCC-
TTCGAAAGAGCAGCAACAGCCTCGACTCTGAGCACTGCACCTCAGATG-
GCTCCACGGAGAC; reverse primer: M13) into the 5 direction so as to
encompass a unique BstbI site present in the 3 region of the 2.3-kb fragment.
This site was then used to subclone each 3 fragment into the plasmid
containing the 0.6- and 2.3-kb fused fragments, producing full-length cDNAs
of Syx1 and Syx2 reaching 3.8 and 4.1 kb, respectively. The cDNA sequences
of Syx1 and Syx2 were deposited at NCBI with accession numbers AY605057
and AY605058, respectively.
DNA and RNA Constructs
Mouse Syx1 and Syx2 cDNA were amplified from their respective pCR2.1-
TOPO constructs so as to avoid the start codon and the 5 region and to
facilitate subcloning into the target plasmids between the BspEI and XhoI sites
(forward primer: GGTGATCACACGTAGTTTCCGGATGTAG; reverse prim-
er: CCGCTCGAGATCTGGGACAGGACCGGGCGTCTC). Syx1 and Syx2
were subcloned into N-terminus fusion versions of vectors pEYFP, pEGFP,
mRFP (all from BD Biosciences, San Diego, CA), and pcDNA4/HisMax
(Invitrogen) between the BglII and BamHI sites. Syx1-specific siRNA (5-
CUCACUGCCUCGGAGGUAUGA-3) was targeted to a 21-base-long se-
quence consisting of 12 bases at the 3 end of exon 20 and 9 at the 5 end of
exon 21, thus preventing full hybridization to the Syx2 transcript. Syx2-
specific siRNA was targeted to a 21-base-long sequence (5-ACTCATGCC-
TGGGAGCATCGCATTT-3) in the intron between exons 20 and 21, which is
present only in the Syx2 transcript. Luciferase-targeted siRNA was used as
negative control. Synectin-specific siRNA (5-GCCGUACAGCUCCUU-
GACA-3) was targeted to the 3 region of the transcript. All siRNA oligos
were synthesized and purchased from Qiagen.
Differential Reverse Transcriptase PCR of Syx1
and Syx2 mRNA
We took advantage of the splicing pattern of the Syx gene in order to design
primers that amplified (Thermo-Script, Invitrogen) either 826- (human), 875-
(rat), and 941 (mouse)-nt-long fragments from Syx1 mRNA, or 1087- (human),
1136- (rat), and 1202 (mouse)-nt-long fragments from Syx2 mRNA. The same
forward and reverse primers were used for both Syx1 and Syx2 amplification.
The forward primers (human: CTCTCAGCACTGTGCCTCAGATG; rat:
CTCTCAGCACTGTGCCTCAGATG; mouse: GGGTGAAGAGAGCGGTAC-
CTCAG) span the 3 region of exon 20 and the 5 region of exon 21. The
reverse primers (human: GCTGTCTCTTGGTCAATGGCAC; rat: GGCAGC-
AGTGAAGCAGGTGC; mouse: GCGGTGAAGCAGGTGCTGTATC) corre-
spond to the 3 UTR. Because Syx2 mRNA contained an additional 3 UTR
fragment, its amplicon is longer by 261 bases (in all 3 species) than the
amplicon generated from the Syx1 mRNA. All reverse transcriptase PCR
results were verified by omitting the reverse transcriptase reaction.
The cell types probed by reverse transcriptase PCR for Syx1 and Syx2
expression were as follows: 1) cells of human origin: umbilical vein endothe-
lial, arterial endothelial, retinal pigment epithelial, immortalized astrocytes,
melanocytes, melanoma, osteosarcoma, glioma, glioblastoma multiforme,
lymphoblastoma, breast cancer epidermal, and pheocromocytoma; 2) cells of
rat origin: rat fat pad ECs (RFPECs), astrocytes, and gliosarcoma; and 3) cells
of mouse origin: heart endothelial, lung endothelial, monocytes, helper T-
lymphocyte, neuroblastoma, lymphoma, and lymphoblastoma.
Real-time PCR
mRNA purified as above was treated by DNase (Ambion, Austin, TX) in
order to remove genomic DNA, reverse-transcribed (ThermoScript, Invitro-
gen) using 1 g with random hexamers and amplified (7500 Real Time PCR
System, Applied Biosystems, Foster City, CA) using primers and annealing
temperatures listed in Table 1. Each sample contained 1 l reverse-transcribed
DNA, 15 l 2 SYBR Green PCR Master Mix (Applied Biosystems), 1 l
forward and 1 l reverse primer (5 pmol/l), in a total volume of 30 l. The
cycling protocol consisted of 2 min at 50°C, 10 min at 95°C, followed by 40
cycles of 15 s at 95°C and 1 min at 60°C.
We calculated the amount of either Syx1 or Syx2 mRNA copy number,
using -actin as an internal control, according to the 2CT method (Livak
and Schmittgen, 2001). The ratio between the mRNA copy numbers of Syx1
and Syx2 in each sample is given by 2CT, where CT is the threshold
fractional cycle number. Syx1/Syx2 ratios represent the average of four
amplification runs, calculated after subtracting the ratios of non–reverse-
transcribed samples that were run in parallel. Validation experiments dem-
onstrated that the amplification efficiencies of both Syx1, Syx2, and -actin
were approximately equal, as required for the 2CT method.
Cell Culture, Transfection, and FACS
RFPECs were grown in M199 with 10% fetal bovine serum (FBS) at 37°C/5%
CO2. Mouse heart ECs from wild-type (WT) or synectin/ mice (a gift of M.
Simons, generated by disruption of the synectin gene with the gene trap
method) were harvested and grown as described (Partovian et al., 2005).
Glioblastoma multiforme (GBM) cell lines and telomerase-immortalized hu-
man astrocytes (both gift of M. Israel, Dartmouth) were grown in DMEM with
10% FBS.
RFPECs were transfected with Syx1 and Syx2 fused to visual fluorescent
proteins (VFP, a generic term for all GFP derivatives) or with siRNA by
FuGENE-6 (Roche) and by Targefect (Targeting Systems, San Diego, CA),
respectively, according to the manufacturer’s instructions. VFP-expressing
cells were sorted (FACStar Plus, Becton Dickinson, Lincoln Park, NJ) into
medium and high expresser populations by separating the top 7–9% and
2–4%, respectively, based on the fluorescence intensity of the fused VFP
moieties. The medium expresser group was used in all experiments in order
to avoid potential artifacts of supraphysiological expression levels.
Antibodies
Chicken polyclonal antibody to mouse Syx was raised and affinity purified
(Aves Labs, Tigard, OR) using a peptide (QHRKLTLAQLYRIRTT) corre-
sponding to residues 1046–1061, which are shared by Syx1 and Syx2. The
corresponding sequences in rat Syx1 and Syx2 are identical. Rabbit affinity-
purified antibody to synectin was produced as described (Dance et al., 2004)
and used at 1 g/ml for immunoblot and 10 g/ml for immunofluorescence.
Rabbit affinity-purified antibody to myosin VI was produced as described
(Hasson and Mooseker, 1994) and used at 1 g/ml for immunoblot. Anti-
bodies for c-Jun N-terminus kinase (JNK) and phospho-JNK were from Cell
Signaling Technology (Beverly, MA). Alexa-647–conjugated phalloidin was
from Molecular Probes (Eugene, OR). -VFP was purchased from BD Bio-
sciences. Peroxidase-conjugated donkey anti-rabbit and donkey anti-chicken
antibodies were from Jackson ImmunoResearch Laboratories (West Grove,
PA). Phalloidin and all purchased antibodies were used at concentrations
recommended by the manufacturers.
Confocal Microscopy
RFPECs or mouse heart ECs were plated on glass coverslips and processed as
described (Horowitz et al., 2002). Images were acquired by laser-scanning
confocal microscopy (Zeiss LSM 510 Meta, Thornwood, NY) with a 63
objective. Plasma membrane (PM) targeting was quantified by counting the
number of cells with PM-localized Syx1 or Syx2 in a total of 100 cells in each
experiment.
Live Cell FRET Imaging
Subconfluent RFPECs were grown on fibronectin-coated (10 ng/ml, 1 h at
37°C) 35-mm plates with optical-quality 1-mm glass bottom (FluoroDish,
Table 1. Sequences and annealing temperatures of primers used in real-time PCR experiments
Gene Forward primer Reverse primer Tm (°C)a
Amplicon
length (bp)
Syx1 CTCACTGCCTCGGAGGTCTG GTCTCTTGGTCAATGGCACTCTT 59.6,58.4 62
Syx2 CTGTGGTGGGCAGCAGTG GACAGAGTCCTTCTTTGGCTGAC 58.3,58.1 108
-Actin TCAACACCCCAGCCATGTAC GGTCAGGATCTTCATGAGGTAGTC 57.9,56.9 203
Sequences were designed by Primer Express (Applied Biosystems) and synthesized by Invitrogen. The Syx1 and Syx2 forward primers span
the 3 region of exon 20 and the 5 region of exon 21. The reverse primers correspond to the 3 UTR.
a Values are for forward and reverse primers, respectively.
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World Precision Instruments, Sarasota, FL). Cells were cotransfected with the
Raichu-RhoA FRET probe pRaichu-1237X (Yoshizaki et al., 2003) and with
mRFP-Syx1 or mRFP-Syx2 constructs. Transfected cells were starved over-
night in M199 medium (Invitrogen) supplemented with 0.25% FBS and 1%
bovine serum albumin overnight. Cells selected for imaging had similar
mRFP emission levels as judged by eye. A series of 50 images at 20-s intervals
was acquired starting at 1 min after cell activation by platelet-derived growth
factor (PDGF) or lysophosphatidic acid (LPA), so as to track the postactivation
increase in the FRET response. Afterward, additional four series of 20 images
at 20-s intervals were acquired every 6 min. Images of cell-free areas of the
plate were acquired for each series and were subtracted from the raw images
(ImagePro, Media Cybernetics, Silver Spring, MD).
Live cell FRET imaging was performed on an inverted microscope
(Olympus IX71, Olympus, Melville, NY) using a plexiglass-enclosed stage
kept at 37°C and 5% CO2. Images were acquired by cooled software-
controlled (QED, Media Cybernetics) charge-coupled device camera (Sen-
siCam, Cooke, Auburn Hills, MI). FRET capability was conferred by a dual
beam splitter with CFP and YFP filters (HQ 465/30m and HQ 560/55m,
respectively, Chroma, Brattleboro, VT). CFP was excited by a white light
source (Lambda DG4, Sutter Instrument, Novato, CA) through a 438/
24-nm filter (FF458-Ex01–25, Semrock) followed by a 20% neutral density
filter and a 60 oil immersion objective (Olympus). Shutters were
switched by a software-controlled driver (VMM-D3, Uniblitz). Exposure
time was set to 0.5 s. After background subtraction, the FRET efficiency
(the ratio of YFP/CFP emissions) was calculated by ImagePro (Madison,
WI). Epifluorescence illumination was generated by a 100-W Xenon lamp
(Olympus).
Cell Function Assays
Gap Closure. Assays were performed as described (Horowitz et al., 2002).
Agonists were applied at the indicated concentrations throughout the assay.
Cells were stimulated by LPA or by PDGF BB (Sigma), an optimal stimulator
of RFPECs migration.
Transwell. Mouse heart ECs were loaded with 5 g/ml calcein (Molecular
Probes) by incubation for 2 h at 37°C in DMEM supplemented with 0.5% FBS.
After detachment by dissociation solution (Cellstripper, Cellgro, Herndon,
VA), 105 cells in 0.25 ml were seeded in Fluoroblock (BD Biosciences, pore
size, 3 m) inserts placed in a 24-well plate. A volume of 0.75 ml medium
containing 5 ng/ml EGF (Sigma), an efficient stimulator of mouse heart EC
migration, was placed in the bottom of the well. Cell migration was quantified
by measuring calcein fluorescence (Synergy HT, using 485/20 and 530/25 nm
filters; Bio-Tek, Winooski, VT) after a 4-h incubation at 37°C/5% CO2. Trans-
well was preferred over gap closure assay with mouse heart ECs because
these cells did not form a well-defined advancing edge.
In Vitro Tube Formation. Twelve-well plates were coated with a2-mm layer
of Matrigel (BD Bioscience) according to the manufacturer’s instructions.
RFPECs, 105, were seeded per well in M199 with 0.5% FBS. Phase-contrast
images of cells at the center of the wells were acquired 12 h after cell seeding.
RhoA Activity. RFPECs were starved for 24 h in M199 with 0.5% FBS and
0.5% bovine serum albumin. Cells treated by LPA (1 M, 10 min at 37°C;
Sigma), PDGF (50 ng/ml, 5 min; BD Biosciences), and either dimethyl sul-
foxide (DMSO) or phosphate-buffered saline, respectively, were lysed and the
RhoA activity was detected either by immunoblotting or by ELISA-based kits
(Cytoskeleton, Denver, CO) according to the manufacturer’s instructions.
RhoA activity was quantified either by densitometry of the immunoblotted
RhoA bands, or by measuring OD492 of the ELISA samples.
JNK Phosphorylation. Cells (104/well) were grown in a 96-well plate over-
night at 37°C/5% CO2 and then starved for 24 h (0.25% fetal calf serum, 0.5%
BSA in DMEM). Cells were treated by LPA (1 M, 10 min at 37°C; Sigma) or
by DMSO and processed for immunodetection of phospho-JNK (T183/Y185)
and total JNK in each well by ELISA according to the manufacturers’ instruc-
tions (CASE JNK kit, SupperArray, Bethesda, MD). Eight wells were used for
each condition and cell type, four of which for the detection of phospho-JNK
and four for detecting total JNK. Primary antibodies were detected by per-
oxidase-conjugated secondary antibody, followed by OD450 measurement
(Multiscan MCC/340, Labsystems). OD450 value of each well was normalized
by OD595 measured after colorimetric detection of the total protein in the well.
JNK phosphorylation levels were presented as a ratio between the normalized
OD450 corresponding to phospho-JNK and to total JNK.
Proliferation. GBM U87 cells, 2000 per well, were seeded in a 96-well plate
and grown in DMEM supplemented with 10% FBS at 37°C/5% CO2. Cells
were transfected by 10 pmol/well Syx2 or luciferase siRNA according to the
manufacturer’s (X-tremeGene; Roche) instructions. The initial size of the cell
population was defined as a baseline value (day 0) and quantified by mea-
suring the OD492 of a colorimetric reaction, following the manufacturer’s
instructions (CellTiter 96 AQueous One, Promega). Similar measurements
were repeated with cells grown for additional 24, 48, and 72 h.
Immunoprecipitation
Confluent RFPECs were lysed in 0.5 ml RIPA buffer supplemented with a
protease inhibitor cocktail (Complete, Roche), precleared by incubation with
20 l protein G plus/protein A-agarose (Pierce, Rockford, IL) slurry for 1 h at
4°C, and incubated with 10 g of the indicated antibody (or 2 l of -VFP)
and 40 l protein G plus/protein A-agarose for 4 h at 4°C. Beads were washed
six times in lysis buffer and bound proteins were eluted by boiling in 40 l
Laemmli buffer for 5 min.
Statistical Analysis
Standard deviations are shown as bars in the histograms. Differences were
considered statistically significant if p  0.05 by t test.
RESULTS
Syx Is Transcribed as Two Nearly Identical
Splice Variants
We found that the gene of the synectin-binding RhoA ex-
change factor (Syx) initially identified by a yeast two-hybrid
screen is transcribed as two splice variants. Strikingly, the
amino acid sequences encoded by these variants differ only
by two residues: one variant (Syx1) is 1073 amino acid long,
whereas the other (Syx2) is shorter by two C-terminus resi-
dues (Figure 1A). Unlike the long splice variant, the C-
terminus of the shorter one does not conform to the consen-
sus sequence of type I PDZ-binding motif.
The Syx gene is located on mouse chromosome 4. The dif-
ference between the transcripts of the two splice variants is
produced by splicing out a 261 nucleotide (nt)-long intron
located between exons 20 and 21 and between the codons of
residues 1071 and 1072. The resulting transcript has a length of
3867 nt and codes for a 1073-residue-long protein (Figure 1A).
When the above intron is not spliced out, transcription ends at
a stop codon located in exon 20 immediately after the codon for
residue 1071. The corresponding transcript is 4128 nt long.
We screened various cell types in order to detect the
expression levels of Syx1 and Syx2. A total of 23 normal and
tumor human, mouse, and rat cell types (see Materials and
Methods for the full list) were probed by reverse transcriptase
PCR. Syx2 expression was low or undetectable in all normal
cells and most malignant cell lines, including RFPECs (unpub-
lished data). The only cell type that expressed Syx2 at a signif-
icant level relative to Syx1 was GBM, the most common and
most malignant primary brain tumor (Stark et al., 2005). The
real time PCR-measured ratios between the mRNA copy
numbers of Syx1 and Syx2 in the GBM cell lines U87 and
SF210 were significantly lower than in human astrocytes
(Figure 1B), which we considered to be a control normal cell
type. Based on these ratios, the Syx2 expression level was 9
and 2.4% in U87 and SF210 cells, respectively, of the Syx1
expression level.
Because of the minimal difference between the sequences
of Syx1 and Syx2, it was not possible to raise antibodies
specific to each isoform. A similarity search with the Syx
cDNA sequence revealed that the human (chromosome 1, as
previously reported; De Toledo et al., 2001), rat (chromo-
some 5), and cow genomes also contain a Syx gene with the
same structure as in the mouse.
Syx Interacts with Synectin and Myosin VI
Because Syx was initially detected as the prey of synectin in a
yeast two-hybrid assay, we sought to confirm the interaction
by coimmunoprecipitation. To begin with, we attempted to
detect Syx itself in RFPEC lysate with an antibody raised
against a 12-residue-long peptide corresponding to a sequence
in the C-termini of both Syx1 and Syx2. The detected band
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migrated at 120 kDa, close to the calculated 119-kDa molec-
ular weight of Syx1 (Figure 1C). A similar-sized band was
previously detected in a Western immunoblot of rat hippocam-
pus (Marx et al., 2005). Endogenous Syx was immunoprecipi-
tated by synectin and vice versa (Figure 1C), confirming the
yeast two-hybrid results and in agreement with the coimmu-
noprecipitation of Syx and synectin coexpressed in 293 cells
(J. Henderson and J. Baraban, Johns Hopkins, personal com-
munication). When we tagged the N-termini of Syx1 and Syx2
with VFP and used this tag for immunoprecipitation from
VFP-Syx1 or VFP-Syx2–expressing RFPECs, only VFP-Syx1
coimmunoprecipitated synectin, whereas VFP-Syx2 did not
(Figure 1D).
Synectin functions as an adaptor between proteins that bind
to its PDZ domain and the actin-based molecular motor myo-
sin VI (Hasson, 2003), which interacts with the C-terminus of
synectin (Reed et al., 2005). Myosin VI was coimmunoprecipi-
tated with VFP-Syx1 but not with VFP-Syx2 (Figure 1D), indi-
cating that myosin VI associated with Syx1 in a synectin-
dependent manner.
Syx Is Targeted in a Synectin-dependent Manner
Given that PDZ adaptor proteins frequently regulate the
targeting of their ligands (Sheng, 2001), we sought to com-
pare the localization of Syx1 and Syx2. In quiescent RFPECs,
endogenously expressed Syx, which is almost exclusively of
the Syx1 isoform (real-time PCR, unpublished data), was
localized in the cytoplasm (Figure 2A). LPA stimulation was
accompanied by the appearance of a Syx1 perinuclear clus-
ter, and by Syx1 targeting to the PM. In LPA-stimulated cells
synectin collocated with Syx1 in both the perinuclear region
and the PM, but there was no collocation of the two proteins
in quiescent cells (Figure 2A). Similar to endogenous Syx1,
VFP-Syx1 localization in quiescent RFPECs was cytoplasmic
(Figure 2B). LPA stimulation was accompanied by an in-
crease in the perinuclear concentration of both VFP-Syx1
and -Syx2. Only VFP-Syx1, however, was targeted to the PM
and to PM-adjacent clusters, similar to endogenous Syx1
(Figure 2B). VFP-Syx1 was targeted to the PM in 54% of
LPA-stimulated RFPECs, whereas VFP-Syx2 was targeted to
the PM in 19% of RFPECs (Figure 3). These results suggest
that the PDZ-binding motif is essential for the PM targeting
of activated Syx.
Conversely, we utilized heart ECs from synectin/ mice
in order to find if the absence of the adaptor protein alters
Syx targeting. As in RFPECs, endogenous Syx in mouse
heart ECs is predominantly of the Syx1 isoform (real-time
PCR, unpublished data). In WT and synectin/ quiescent
heart ECs, Syx1 was distributed homogenously in the cyto-
plasm (Figure 2C). Upon LPA-stimulation a concentrated
Figure 1. Gene and mRNA structure, expression levels, and mo-
lecular interactions of Syx. (A) Structure of the Syx gene and mRNA
near the 3 region of the coding region and domain map of Syx. (B)
Ratios between the mRNA copy numbers of Syx1 and Syx (Syx1/
Syx2) were calculated according to the 2CT method (Livak and
Schmittgen, 2001), using -actin as an internal control. The Syx1/
Syx2 ratios represent the average of four (SD) amplification runs,
calculated after subtracting the ratios of non–reverse-transcribed
samples that were run in parallel. (C) Immunoprecipitation of syn-
ectin by anti ()-Syx1 and vice versa. RFPEC lysates were immuno-
precipitated (IP), resolved by SDS-PAGE and immunoblotted (IB) as
indicated: lane 1, nonimmune chicken IgY; lane 2, RFPEC lysate;
lane 3, anti-Syx IP; lane 4, ni rabbit IgG; lane 5, anti-synectin IP; lane
6, RFPEC lysate. Arrow, synectin band; arrowhead: Syx1 band. (D)
VFP-Syx1 but not VFP-Syx2 immunoprecipitated synectin. Samples
were processed as in C. Lane 1, anti-VFP IP from lysate of VFP-
Syx1–expressing RFPECs; lane 2, nonimmune IgG IP from lysate of
VFP-Syx1–expressing RFPECs; lane 3, anti-VFP IP from lysate of
VFP-Syx2–expressing RFPECs. Anti-Syx immunoprecipitated myo6
only from VFP-Syx1–expressing RFPECs: lane 4, anti-VFP IP from
lysate of VFP-Syx2–expressing RFPECs; lane 5, anti-VFP IP from
lysate of VFP-Syx1–expressing RFPECs; lane 6, RFPEC lysate; ar-
row, synectin band; arrowhead, myo6 band.
Figure 2. Localization of Syx1 and Syx2. (A) Localization of en-
dogenous Syx and synectin in quiescent and LPA-stimulated (1 M,
10 min) RFPECs (nuclear labeling is nonspecific). WT cells were
fixed, permeabilized, and immunolabeled with the indicated anti-
bodies, followed by fluorescently labeled anti-chicken IgY and anti-
rabbit IgG. Syx and synectin collocated (arrows) in LPA-stimulated
cells, but not in quiescent ones. Cells were fixed, permeabilized, and
immunolabeled by anti-Syx, followed by fluorescently labeled anti-
chicken IgY. (B) Localization of VFP-Syx1 or VFP-Syx2 in quiescent
and LPA-stimulated RFPECs (fields are shown in triplicate; arrows
point to VFP-Syx1 on the PM), which were transiently transfected
by each of the two splice variants and fixed 24 h posttransfection.
(C) Localization of endogenous Syx1 in WT and in synectin/
mouse heart ECs. All images were acquired by confocal microscopy.
Scale bars, 10 m; 5 m in insets.
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perinuclear Syx1 population appeared both in WT and syn-
ectin/ heart ECs (Figure 2C), but PM targeting occurred
only in the WT cells (Figure 2C). Syx1 was targeted to the
PM in 35% of WT heart ECs, but virtually in none of the
synectin/ heart ECs (Figure 3). This result complements
the evidence gathered from VFP-Syx1– and VFP-Syx2–ex-
pressing RFPECs for the dependence of PM targeting of Syx
on its interaction with synectin.
Syx1 and Syx2 Produce Different Spatial Patterns
of RhoA Activity
The differences between the localization of each Syx iso-
form may confer corresponding changes in the level and
spatial distribution of RhoA activity. Initially, in order to
assess the relative contribution of Syx1 to the overall
RhoA activity level in RFPECs, we compared the results
of RhoA assays of RFPECs transfected either by Syx1-
specific or by control siRNA. The RhoA activation level in
RFPECs transfected by Syx1-specific siRNA was reduced
by 50% relative to RFPECs treated by control siRNA
(Figure 4A), indicating that endogenous Syx1 is responsi-
ble for the activation of a major part of the total RhoA pool
in RFPECs in response to LPA.
The global level of active RhoA in LPA-treated RFPECs
expressing Syx1 was similar to that of Syx2-expressing cells
(Figure 4B), indicating that Syx2 activates RhoA as efficiently
as Syx1 in response to LPA. Surprisingly, however, the basal
RhoA activity level was 70% higher in Syx2-expressing cells.
The basal as well as the LPA-stimulated global levels of
RhoA activity cannot account, therefore, for the higher mi-
gration rate of Syx1- versus Syx2-expressing cells.
We anticipated that the spatial patterns of RhoA activity
may reflect the observed differences in the localization of
each Syx isoform. For that purpose we imaged RFPECs
cotransfected by either mRFP-Syx1 or mRFP-Syx2 and by a
RhoA FRET probe that emits light in the YFP range only
upon GTP binding to the RhoA moiety in the probe (Yo-
shizaki et al., 2003).
In unstimulated RFPECs expressing mRFP-Syx1, RhoA
activity was low across the cells except for the PM (Figure
5A). In quiescent mRFP-Syx2–expressing cells, however,
there was a higher level of active RhoA across the cell, likely
reflecting the diffuse cytoplasmic distribution of Syx2 (see
Figure 2B). On LPA stimulation, Syx1-expressing RFPECs
exhibited highly increased RhoA activity along the PM (Fig-
ure 5B). Though the level of active cytoplasmic RhoA in
Syx2-expressing RFPECs increased significantly relative to
quiescent Syx2-expressing cells, the spatial pattern remained
diffuse without the higher PM-associated activity seen in
Syx1-expressing cells. PDGF treatment was accompanied by
similar differences between the activation patterns of RhoA
in Syx1- versus Syx2-expressing cells (Figure 5C).
Syx1 and Syx2 Have Contrasting Effects on EC Function
Because cell migration requires spatial and temporal coor-
dination of GTPase activity (Fukata et al., 2003), the dispar-
ate patterns of active RhoA in Syx1- versus Syx2-expressing
RFPECs could conceivably produce differences in the migra-
tion rates of each cell group.
Both unstimulated and PDGF- or LPA-treated RFPECs
expressing Syx1 migrated threefold faster than vector-trans-
fected control cells in gap closure assays (Figure 6A). Ex-
pression of Syx2, however, did not augment migration rel-
ative to vector-transfected cells. These results suggest that
although the diffusely distributed Syx2 was less effective in
supporting migration, it did not interfere with the function
of endogenous Syx1.
Because Syx1 interacts with synectin, we tested synectin’s
contribution to EC migration by transfecting Syx1-express-
ing RFPECs with synectin-specific siRNA. Silencing of syn-
ectin expression by more than 90% inhibited migration to an
extent very similar to that of Syx1-specific siRNA (Figure
6B). We further investigated the involvement of synectin in
cell migration by comparing the migration rates of ECs from
hearts of WT mice to those of synectin/ mice. ECs from
WT mice migrated twice as fast as ECs of synectin/ mice
Figure 3. Quantification of PM targeting of Syx1 and Syx2. Percent
of RFPECs imaged as in Figure 2B in which either VFP-Syx1 or
VFP-Syx2 were targeted to the PM; percent of WT or synectin/
mouse heart ECs imaged as in Figure 2C in which endogenous Syx1
was targeted to the PM. One hundred cells were counted in each of
three different experiments with each cell type (SD; * p  0.05).
Figure 4. Contribution of Syx1 and Syx2 to global RhoA activity in
RFPECs. (A) Relative contribution of Syx1 to RhoA activation. Im-
munoblots (in duplicate) of active RhoA and of total RhoA in lysates
of WT RFPECs transfected by either Syx1-specific or control siRNA
and activated by LPA. Means represent the densitometric values of
the duplicate bands of active RhoA shown in A, normalized by the
corresponding values of the total RhoA bands. (B) Global RhoA
activity in quiescent (f) and LPA-treated (1 M, 10 min;) RFPECs
expressing each of the indicated Syx splice isoforms. Means repre-
sent ratios between OD492 of active and total RhoA of each sample
after normalization by the mean of the quiescent Syx1 samples (n 
6, SD; * p  0.05).
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in response to EGF in a Transwell assay (Figure 6C). These
results show that interaction with synectin is required for
the contribution of Syx1 to cell migration.
In vitro tube formation or angiogenesis is a major func-
tional marker of ECs and is regulated by RhoA (van Nieuw
Amerongen et al., 2003). Similar to the effects on RFPEC
migration, cells expressing Syx1 formed a continuous tubu-
lar network when grown on extracellular matrix substrate
with 0.5% serum, whereas Syx2-expressing cells formed
very few tubes, far less than the incomplete network formed
by vector-transfected RFPECs (Figure 6D).
Syx2 Is Expressed in Brain Tumor Cells
Because we detected significant expression levels of Syx2
only in GBM cell lines, (Figure 1B), we hypothesized that
this expression pattern is linked to tumorigenicity and that
similar to Syx2-transfected RFPECs, the basal activity level
of RhoA may be higher in GBM cells than in normal astro-
cytes. That, in turn, could contribute to the malignant trans-
formation of these cells via transcription factors downstream
of RhoA. Similar to Syx2-expressing RFPECs, the RhoA ac-
tivity levels of LPA-treated astrocytes and GBM cells were
comparable (Figure 7A), but the basal RhoA activity level
was more than twofold higher in the two GBM cell lines we
assayed. It appears, therefore, that even a relatively modest
expression level of Syx2 (e.g., 9% of Syx1 expression level in
U87 cells, Figure 1B) is sufficient to sustain elevated basal
RhoA activity.
RhoA regulates the expression of the c-Jun transcription
factor through a pathway separate from RhoA-dependent
regulation of the actin cytoskeleton. That pathway uses JNK
(Marinissen et al., 2004), which is activated upon phosphor-
ylation of Thr183 and Tyr185 (Derijard et al., 1994). Subse-
quently JNK phosphorylates transcription factors bound to
the c-Jun promoter (Davis, 2000), thus increasing cell prolif-
eration. JNK phosphorylation level was significantly higher
in quiescent GBM U87 cells than in quiescent astrocytes and
was not further increased by LPA treatment (Figure 7B), in
agreement with the possibility that the higher level of basal
RhoA activity in GBM cells resulted in up-regulation of
downstream transcription factors.
U87 GBM cells transfected by Syx2-specific siRNA prolif-
erated significantly slower than cells treated by control
siRNA (Figure 7C), confirming that Syx2 expression is asso-
ciated with the elevated growth rate typical of malignant
cells.
DISCUSSION
Previously reported functions of PDZ motifs in Rho GEFs
concerned mainly targeting, as in the case of Kalirin-7 that
required the PDZ motif for positioning in dendritic spines.
Mutant Kalirin-7 lacking this motif was diffusely distributed
in the cytoplasm (Penzes et al., 2001), similar to Syx2. The
dependence of Rac1 activation by Kalirin-7 on the engage-
ment of its PDZ-binding motif was not clear cut, however,
because PSD-95 down-regulated Rac1 activation by both WT
Figure 5. FRET-imaged RhoA activity in
Syx1- and Syx2-expressing RFPECs. Duplicate
FRET images of RFPECs expressing the
Raichu-RhoA YFP-CFP probe and each of the
indicated mRFP-Syx constructs. Cells were ei-
ther quiescent (A) or stimulated by LPA (B, 1
M, 10 min) or by PDGF (C, 50 ng/ml, 5 min).
FRET efficiency is displayed as a thermal map
corresponding to the scale shown in A. The
smaller images in B and C show a time series
corresponding to the larger image above on the
left. Live cell FRET images were acquired as
described in Materials andMethods. Scale bar, 10
m.
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and a Kalirin-7 mutant lacking the PDZ-binding motif. Sim-
ilarly, conflicting results were reported regarding the depen-
dence of the transforming activity of Net1 on its PDZ-bind-
ing motif (Qin et al., 2005), where a mutant lacking the
PDZ-binding motif was less efficient in transforming 3T3
fibroblasts, but a splice variant with a PDZ-binding motif
was similarly inefficient. A previous study where expression
of a Syx1 human orthologue was shown to transform 3T3
fibroblasts used a partial clone (GEF720) lacking 160 N-
terminus residues (De Toledo et al., 2001) but containing the
PDZ-binding motif. This truncated version of Syx1 may
have been disinhibited, however, because the N-terminus is
required for the down-regulation of Syx1 (Marx et al., 2005).
Therefore, this result does not necessarily reflect the trans-
formation potential of full-length Syx1, which is likely to be
lower than that of GEF720.
The failure of Syx2 expression to augment cell migration
in the same manner as Syx1 suggests that the PDZ-binding
motif and the interaction with synectin are required for the
functional coupling of Syx to the actin cytoskeleton. A sec-
ond possible consequence of the absence of a PDZ-binding
motif and the diffuse distribution in the cytoplasm is re-
duced catalytic regulation, as indicated by the higher basal
RhoA activity in Syx2-expressing RFPECs and in GBM cells.
The lower regulation of Syx2 could result from better access
to the cytoplasmic pool of RhoA or its inability to associate
with other proteins required for regulating Syx2 itself
and/or RhoA.
The association of myosin VI with the complex containing
Syx1 and synectin probably links Syx1 to the actin cytoskel-
eton and could facilitate translocation of the complex in the
retrograde direction along actin filaments (Wells et al., 1999).
Because synectin is associated with endocytic vesicles (As-
chenbrenner et al., 2003), the specific function of Syx1 may
Figure 6. Functional assays of Syx1- and Syx2-expressing RFPECs.
(A) Gap closure by quiescent, PDGF- (50 ng/ml) or LPA- (1 M)
treated RFPECs stably expressing VFP-Syx1, VFP-Syx2, or VFP
alone. A confluent monolayer of serum-starved RFPECs was
scratched before treatment, and the gap width was measured im-
mediately before (W0) and after (W6) a 6-h incubation (W  W0 
W6). Inset, immunoblot showing the total expression level of Syx in
WT (lane 1), or of VFP-Syx2 (lane 2), and VFP-Syx1 (lane 3) in
transfected RFPECs. (B) Gap closure by RFPECs transfected by each
of the indicated siRNA species and treated as in A. Inset, immuno-
blot showing the expression levels of synectin and of Syx in RFPECs
transfected by siRNA specific to synectin (lane 2), Syx1 (lane 4), or
by control siRNA (lanes 1 and 3). (C) Migration rates of quiescent or
EGF (5 ng/ml)-treated heart ECs from WT or from synectin/
mice in Transwell assays, quantified by spectrometry of fluores-
cently labeled migrated cells at 530 nm, as described in Materials and
Methods (AU, arbitrary units). (D) In vitro tube formation assays by
RFPECs expressing the indicated constructs in the presence of 0.5%
serum. RFPECs were seeded in Matrigel-coated plates and imaged
12 h later.
Figure 7. Basal RhoA and JNK activity, and proliferation rate in
GBM cells are higher than in normal astrocytes. (A) Global RhoA
activity levels in lysates of quiescent (f) and LPA-treated (1 M, 10
min; ) astrocytes and GBM cell lines U87 and SF210, assayed by
ELISA, and measured by OD492. Means represent ratios between
OD492 of active and total RhoA of each sample (see Materials and
Methods) after normalization by the mean of the same ratios of quies-
cent cells (n  4, SD; * p  0.05). (B) Levels of phospho-JNK in
quiescent (f) and LPA-treated (1 M, 10 min; ) normal astrocytes
and U87 GBM cell line, assayed by ELISA, and presented as ratios
between the OD450 of anti-phospho-JNK and the OD595 of anti-pan
JNK. The absorbances were previously normalized by the sizes of the
cell populations of each sample (n  4, SD; * p  0.05). (C) Prolifer-
ation rates of GBM cell line U87 treated by siRNA specific to Syx2 ()
or by control siRNA (f), presented as ratios between the cell popula-
tion size on each day and the initial population size (n 4,SD; * p
0.05).
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involve rearrangement of the actin cytoskeleton during in-
ward vesicle traffic. In support of this possibility, we ob-
served collocation between Syx1 and several markers of
early endosomes (unpublished data).
Possibly the most intriguing question is the biological
significance of the existence of almost identical Rho GEF
splice variants. Because we were able to detect a significant
level of Syx2 expression only in malignant cells, we hypoth-
esize that the less tightly regulated Syx2, which gives rise to
a sustained basal level of RhoA activity, up-regulates tumor-
igenic transcription factors. Association between tumorige-
nicity and Syx2 expression is suggested also by a previous
study, which reported that synectin degradation mediated
via its interaction with the viral oncoprotein E6, as well as
RNAi silencing of synectin, increased cell proliferation
(Favre-Bonvin et al., 2005). Together with the results pre-
sented here, this initial data set suggests a novel mechanism
of malignant transformation that does not involve trunca-
tion of proto-oncogenic Rho GEF (Ron et al., 1989), but rather
the expression of an unmodified and loosely targeted Rho
GEF splice variant.
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